Edition:
India

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

2.85USD
19 Aug 2019
Change (% chg)

$0.14 (+5.17%)
Prev Close
$2.71
Open
$2.74
Day's High
$2.97
Day's Low
$2.70
Volume
462,947
Avg. Vol
550,725
52-wk High
$19.54
52-wk Low
$2.35

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  AKRX.OQ Industry Sector
P/E (TTM): 33.22 29.89 32.67
EPS (TTM): 0.99 -- --
ROI: 6.80 14.89 14.48
ROE: 14.90 16.01 15.78

Why would allegedly defrauded Akorn investors want … more Akorn stock?

The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The U.S. Food and Drug Administration is investigating data integrity issues at the company’s manufacturing plants, issuing two warning letters this year about potential regulatory shortcomings. Akorn is also feeling p

13 Aug 2019

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

25 Jun 2019

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

25 Jun 2019

UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant

June 25 Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

25 Jun 2019

Akorn gets FDA's warning letter related to New Jersey manufacturing plant

June 25 Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to the inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018.

25 Jun 2019

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

28 Feb 2019

UPDATE 2-FDA flags concerns at Akorn's Amityville plant, shares slip

Feb 28 Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

28 Feb 2019

FDA flags sanitation concerns at Akorn's Amityville plant

Feb 28 Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.

28 Feb 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates